Evidence map›Paper›PMID 34391872›Full record

Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2022

Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.

Godela M Brosnahan, Wei Wang, Berenice Gitomer, Taylor Struemph, Diana George, Zhiying You, Kristen L Nowak, Jelena Klawitter, Michel B Chonchol

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02903511 (Feasibility Study of Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease.), which is not on this map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02903511 phase2completednot on this map

Feasibility Study of Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease.

TypeinterventionalSponsorUniversity of Colorado, DenverRan2016 to 2020Enrolled56ConditionsPolycystic Kidney, Autosomal DominantArmsMetformin, Placebo
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Metformin for preventing the progression of chronic kidney disease.The Cochrane database of systematic reviews · 2024 · on this map
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. The Role of Mitochondria in Polycystic Kidney Disease.International journal of molecular sciences · 2026
    Review
  10. End Point Selection in ADPKD Clinical Trials.Kidney international reports · 2025
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Godela M BrosnahanDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado. Electronic address: godela.brosnahan@cuanschutz.edu.
Wei WangDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Berenice GitomerDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Taylor StruemphDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Diana GeorgeDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Zhiying YouDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Kristen L NowakDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Jelena KlawitterDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Michel B ChoncholDivision of Renal Diseases and Hypertension, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
University of Colorado Anschutz Medical Campus · US

Funding

PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · UNIVERSITY OF COLORADO DENVER · 1995 to 2025
$7.7M
NIDDK NIH HHS P30 DK048520NIDDK NIH HHS R21 DK107969
6 · The paper itself

Abstract

RATIONALE &

objectiveAutosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that leads to kidney failure and has few treatment options. Metformin is well tolerated and safe in other patient populations. The primary objective of this clinical trial was to determine the safety and tolerability of metformin in patients with ADPKD and without diabetes mellitus. STUDY

designProspective randomized controlled double-blind clinical trial. SETTING &

participants51 adults aged 30-60 years with ADPKD, without diabetes, and an estimated glomerular filtration rate (eGFR) 50-80 mL/min/1.73 m EXPOSURE: Metformin (maximum dose 2,000 mg/d) or placebo for 12 months. OUTCOME: Coprimary end points were the percentage of participants in each group prescribed at the end of the 12-month period: (1) the full randomized dose or (2) at least 50% of the randomized dose. Secondary and exploratory outcomes were the effect of metformin compared with placebo on (1) the percentage change in total kidney volume (TKV) referenced to height (htTKV in mL/m) and (2) the change in eGFR over a 12-month period.

resultsThe participants' mean age was 48 ± 8 (SD) years, and eGFR was 70 ± 14 mL/min/1.73 m LIMITATIONS: Short study duration.

conclusionsWe found that 50% or more of the maximal metformin dose was safe and well tolerated over 12 months in patients with ADPKD. Safety of other preparations of metformin as well as its efficacy should be tested in future clinical trials.

fundingGovernment and philanthropic grants (NIDDK and the Zell Foundation).

trial registrationRegistered at ClinicalTrials.gov with study number NCT02903511.

Indexed as

MetforminPolycystic Kidney, Autosomal DominantAdultDisease ProgressionFeasibility StudiesGlomerular Filtration RateHumansKidneyMiddle AgedProspective StudiesMetforminADPKD progressionAMPK activatorautosomal dominant polycystic kidney disease (ADPKD)dose escalationestimated glomerular filtration rate (eGFR)gastrointestinal symptomsmetforminrandomized controlled trial (RCT)renal function declinesafetytolerabilitytotal kidney volume (TKV)

Identifiers

PMID34391872
PMCPMC8837717
OpenAlexW3192198801

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.